11ª edição

OlympiA study evaluates use of olaparib in HER2-negative disease with BRCA 1 and BRCA 2 mutations

per: Grupo Oncoclínicas
OlympiA study evaluates use of olaparib in HER2-negative disease with BRCA 1 and BRCA 2 mutations

Scientific commission

Aline Gonçalves
Aline Gonçalves
Bruno Ferrari
Bruno Ferrari
Carlos Barrios
Carlos Barrios
Daniel Gimenes
Daniel Gimenes
Max Mano
Max Mano

Contributors

Maria Cristina Figueroa
Maria Cristina Figueroa

The phase 3, double-blind, randomized OlympiA study, which followed 1,800 patients at high risk of recurrence, selected those with the BRCA 1 mutation associated with triple-negative tumors and the BRCA 2 mutation with the highest association. with hormone receptor (HR) positive tumors and previously exposed to chemotherapy. The action of adjuvant olaparib in this subgroup was evaluated.

According to clinical oncologist Maria Cristina Figueroa, from Grupo Oncoclínicas de Curitiba, they were divided into two arms: to receive olaparib at a dose of 300 mg/day or adjuvant placebo for one year, starting 2 to 12 weeks after completing the standard treatment with neoadjuvant or adjuvant chemotherapy and radiotherapy, when indicated. The study results were significant in favor of using olaparib to reduce the risk of incidence. “The gain in invasive disease-free survival was significant, especially when dealing with a disease with a high risk of recurrence. The OlympiA study demonstrated a significant reduction, after one year of olaparib, in invasive recurrences, second malignancies, and distant events,” she comments.

Visit our website and read the full article with all the details of this study, as well as other topics discussed at the ASCO 2021 congress.

Access the full article of this study
Download
Share
Or share the link
Link copied to your desktop.L